The combination of both radiotracers allowed for the distinction of breast cancer subtypes with regard to the receptor status (i.e., expression of the estrogen receptor, progesterone receptor, and Human Epidermal Growth Factor Receptor 2), although the underlying mechanisms still need to be identified. Here, ESR1 is linked to breast cancer.